首頁 > 市場調查報告書 > 製藥

生物製劑分子標靶治療學

市場調查報告書

商品編碼

1781937

雙特異性抗體市場，按藥物類型、按適應症、按配銷通路、按國家和地區 - 2025 年至 2032 年全球行業分析、市場規模、市場佔有率和預測

Bispecific Antibodies Market, By Drug Type, By Indication, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

出版日期: 2025年06月04日 | 出版商:

AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

報告重點

2024 年雙特異性抗體市場規模價值 109.9209 億美元，2025 年至 2032 年的複合年成長率為 40.10%。

雙特異性抗體市場-市場動態

增加FDA批准以推動市場需求

雙特異性抗體療法的認可不斷增加，推動了市場擴張。美國食品藥物管理局（FDA）在2022年至2024年間批准了6種雙特異性抗體，反映出監管機構對創新癌症治療的支持力道不斷增加。此外，日益加重的癌症負擔也加速了對先進免疫療法的需求，促使人們投資於雙特異性抗體等標靶療法。然而，複雜的生產流程和高昂的開發成本仍然是雙特異性抗體市場成長的挑戰。相反，政府對癌症研究的資助正在拓展創新潛力，這為全球雙特異性抗體市場提供了巨大的成長機會。

雙特異性抗體市場－關鍵見解

根據我們的研究分析師的分析，預計全球市場在預測期內（2025-2032 年）的年複合成長率約為 40.10%。

根據藥物類型細分，免疫球蛋白 G 預計在 2024 年佔據最大市場佔有率

根據適應症細分，癌症是 2024 年的主要適應症

按地區分類，北美是 2024 年最大的收入來源

雙特異性抗體市場-細分分析：

全球雙特異性抗體市場根據藥物類型、適應症、配銷通路和地區進行細分。

根據適應症，市場分為三類：發炎和自體免疫疾病、癌症和其他。預計在預測期內，癌症領域將佔據主要市場佔有率。這主要得益於全球癌症負擔的不斷增加，以及雙特異性抗體在靶向腫瘤細胞和活化免疫反應方面取得的巨大臨床成功。

根據配銷通路，市場分為四類：藥局、零售藥局、醫院藥局和線上藥局。預計醫院藥局將佔據主要市場佔有率。這是因為雙特異性抗體主要用於癌症和自體免疫疾病等複雜疾病，這些疾病需要專門的給藥、監測和住院護理。

雙特異性抗體市場—地理洞察

在預測期內，北美地區預計將佔據全球雙特異性抗體市場的主要佔有率，這得益於先進的醫療保健基礎設施、強大的研發投資以及美國 FDA 等機構的早期監管批准。

另一方面，由於癌症盛行率上升、臨床試驗活動增加、醫療保健覆蓋範圍擴大以及中國、印度和韓國等國家生物製藥投資不斷成長，預計亞太地區將以最快的速度成長。

雙特異性抗體市場-競爭格局：

標靶免疫療法需求的不斷成長加劇了競爭，促使各公司採取以創新、臨床開發和監管批准為重點的策略。各公司正大力投資研發，以增強雙特異性抗體的劑型、改善安全性並提高其在癌症和自體免疫療法中的療效。策略合作、授權交易以及向新興市場的擴張也是關鍵策略。此外，各公司正在利用先進的平台和專有技術來加速研發管線的進展，並在快速發展的治療領域中確保長期競爭優勢。

介紹
- 按地區分類的細分市場佔有率分析
北美洲
- 概述
- 北美雙特異性抗體主要製造商
- 北美市場規模及預測（按國家/地區）
- 北美市場規模及預測（依藥品類型）
- 北美市場規模及預測（按適應症）
- 北美市場規模及預測（按配銷通路）
- 美國
- 加拿大
歐洲
- 概述
- 歐洲雙特異性抗體主要製造商
- 歐洲市場規模及預測（按國家/地區）
- 歐洲市場規模及預測（依藥品類型）
- 歐洲市場規模及預測（按適應症）
- 歐洲市場規模及預測（按配銷通路）
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 荷蘭
- 瑞典
- 俄羅斯
- 波蘭
- 歐洲其他地區
亞太地區 (APAC)
- 概述
- 亞太地區雙特異性抗體主要製造商
- 亞太地區市場規模及預測（依國家）
- 亞太地區市場規模及預測（依藥品類型）
- 亞太地區市場規模及預測（依適應症）
- 亞太地區市場規模及預測（按配銷通路）
- 中國
- 印度
- 日本
- 韓國
- 澳洲
- 印尼
- 泰國
- 菲律賓
- 亞太地區其他地區
拉丁美洲（LATAM）
- 概述
- 拉丁美洲雙特異性抗體主要製造商
- 拉丁美洲市場規模及預測（按國家/地區）
- 拉丁美洲市場規模及預測（按藥物類型）
- 拉丁美洲市場規模及預測（按適應症）
- 拉丁美洲市場規模及預測（按配銷通路）
- 巴西
- 墨西哥
- 阿根廷
- 哥倫比亞
- 拉丁美洲其他地區
中東和非洲（MEA）
- 概述
- 中東和非洲雙特異性抗體主要製造商
- MEA 市場規模及預測（依國家/地區）
- MEA 市場規模及預測（依藥物類型）
- MEA 市場規模及預測（依適應症）
- MEA 市場規模及預測（依配銷通路）
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 以色列
- 土耳其
- 阿爾及利亞
- 埃及
- MEA 其餘地區

第 11 章：雙特異性抗體產業關鍵供應商分析

競爭儀錶板
- Competitive Benchmarking
- Competitive Positioning
公司簡介
- Amgen
- Genentech
- Akeso, Inc.
- Taisho Pharmaceutical
- Janssen
- Immunocore
- Adimab, Innovent Biologics, Inc.
- AstraZeneca
- Affimed GmbH
- Xencor
- F. Hoffmann-La Roche Ltd.
- Sanofi
- Regeneron Pharmaceuticals Inc.
- Pieris Pharmaceuticals, Inc.
- Eli Lilly
- Mereo BioPharma Group plc
- Merus
- MacroGenics, Inc.
- Sobi, TG Therapeutics Inc.
- Genmab A/S
- Alteogen
- Emergent BioSolutions Inc.
- Novartis AG
- Astellas Pharma Inc.
- Celgene Corporation
- Others

第 12 章：360 度分析師視角

第 13 章：附錄

研究方法
參考
縮寫
免責聲明
聯絡我們

簡介目錄

Product Code: ANV5388

REPORT HIGHLIGHT

Bispecific antibodies market size was valued at US$ 10,992.09 Million in 2024, expanding at a CAGR of 40.10% from 2025 to 2032.

Bispecific antibodies are engineered proteins designed to recognize and bind to two different antigens simultaneously. Unlike traditional monoclonal antibodies that target a single molecule, bispecific antibodies can engage two targets, such as a cancer cell and a T-cell, enhancing immune response and therapeutic precision. This dual-targeting ability makes them highly effective in treating complex diseases like cancer, autoimmune disorders, and infectious diseases, offering improved outcomes and reduced off-target effects.

Bispecific Antibodies Market- Market Dynamics

Increasing FDA approvals to propel market demand

The growing approval of bispecific therapies is driving market expansion, with the U.S. FDA approving 6 bispecific antibodies between 2022 and 2024, reflecting rising regulatory support for innovative cancer treatments. Besides, increasing cancer burden is accelerating demand for advanced immunotherapies, prompting investment in targeted therapeutics like bispecific antibodies. However, complex manufacturing processes and the high development costs continue to challenge bispecific antibodies market growth. On the contrary, government funding for cancer research is expanding innovation potential, which is providing massive growth opportunities for the global bispecific antibodies market.

Bispecific Antibodies Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 40.10% over the forecast period (2025-2032)

Based on Drug Type segmentation, immunoglobulin G was predicted to show maximum market share in the year 2024

Based on Indication segmentation, cancer was the leading Indication in 2024

On the basis of region, North America was the leading revenue generator in 2024

Bispecific Antibodies Market- Segmentation Analysis:

The Global Bispecific Antibodies Market is segmented on the basis of Drug Type, Indication, Distribution Channel, and Region.

The market is divided into three categories based on Indication: inflammatory & autoimmune disorder, cancer, and others. The cancer segment is expected to hold the major market share during the forecast period. This is primarily driven by the growing global cancer burden and the strong clinical success of bispecific antibodies in targeting tumor cells and activating immune responses.

The market is divided into four categories based on Distribution Channel: drug stores, retail pharmacies, hospital pharmacies, and online pharmacies. The hospital pharmacies sector is expected to hold the major market share. This is because bispecific antibodies are primarily used in complex conditions like cancer and autoimmune diseases, which require specialized administration, monitoring, and inpatient care.

Bispecific Antibodies Market- Geographical Insights

The North America region is expected to hold the major market share in the global bispecific antibodies market during the forecast period, driven by advanced healthcare infrastructure, strong R&D investments, and early regulatory approvals by agencies like the U.S. FDA.

On the other hand, the Asia-Pacific region is projected to grow at the fastest rate, owing to rising cancer prevalence, increasing clinical trial activity, expanding healthcare access, and growing biopharmaceutical investments in countries such as China, India, and South Korea.

Bispecific Antibodies Market- Competitive Landscape:

Growing demand for targeted immunotherapies is intensifying competition, pushing companies to adopt strategies focused on innovation, clinical development, and regulatory approvals. Firms are investing heavily in R&D to enhance bispecific antibody formats, improve safety profiles, and increase efficacy in cancer and autoimmune treatments. Strategic collaborations, licensing deals, and expansion into emerging markets are also key approaches. Additionally, players are leveraging advanced platforms and proprietary technologies to accelerate pipeline progress and secure long-term competitive advantages in a rapidly evolving therapeutic landscape.

Recent Developments:

In March 2025, SanyouBio launched 73 bispecific antibody reference products covering approved and clinical-stage drugs, aiming to support drug development and address challenges by enabling dual-target binding to overcome limitations like resistance seen in single-target therapies.

In April 2025, Invenra Inc. announced the launch of its B-Body Express(TM) Antibody Expression service, allowing biotech and pharma companies rapid access to high-purity, validated bispecific antibodies from partner sequences, accelerating preclinical research with speed and advanced technology.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BISPECIFIC ANTIBODIES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Amgen
Genentech
Akeso, Inc.
Taisho Pharmaceutical
Janssen
Immunocore
Adimab, Innovent Biologics, Inc.
AstraZeneca
Affimed GmbH
Xencor
F. Hoffmann-La Roche Ltd.
Sanofi
Regeneron Pharmaceuticals Inc.
Pieris Pharmaceuticals, Inc.
Eli Lilly
Mereo BioPharma Group plc
Merus
MacroGenics, Inc.
Sobi, TG Therapeutics Inc.
Genmab A/S
Alteogen
Emergent BioSolutions Inc.
Novartis AG
Astellas Pharma Inc.
Celgene Corporation
Others

GLOBAL BISPECIFIC ANTIBODIES MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

Immunoglobulin G
Non-Immunoglobulin G

GLOBAL BISPECIFIC ANTIBODIES MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

Inflammatory & Autoimmune Disorder
Cancer
Others

GLOBAL BISPECIFIC ANTIBODIES MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

Drug Stores
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

GLOBAL BISPECIFIC ANTIBODIES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Bispecific Antibodies Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Bispecific Antibodies Market Snippet by Drug Type
- 2.1.2. Bispecific Antibodies Market Snippet by Indication
- 2.1.3. Bispecific Antibodies Market Snippet by Distribution Channel
- 2.1.4. Bispecific Antibodies Market Snippet by Country
- 2.1.5. Bispecific Antibodies Market Snippet by Region
2.2. Competitive Insights

3. Bispecific Antibodies Key Market Trends

3.1. Bispecific Antibodies Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Bispecific Antibodies Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Bispecific Antibodies Market Opportunities
3.4. Bispecific Antibodies Market Future Trends

4. Bispecific Antibodies Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Bispecific Antibodies Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Bispecific Antibodies Market Landscape

6.1. Bispecific Antibodies Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Bispecific Antibodies Market - By Drug Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Drug Type, 2024 & 2032 (%)
- 7.1.2. Immunoglobulin G
- 7.1.3. Non-immunoglobulin G

8. Bispecific Antibodies Market - By Indication

8.1. Overview
- 8.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
- 8.1.2. Inflammatory & Autoimmune Disorder
- 8.1.3. Cancer
- 8.1.4. Others

9. Bispecific Antibodies Market - By Distribution Channel

9.1. Overview
- 9.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
- 9.1.2. Drug Stores
- 9.1.3. Retail Pharmacies
- 9.1.4. Hospital Pharmacies
- 9.1.5. Online Pharmacies

10. Bispecific Antibodies Market- By Geography

10.1. Introduction
- 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
10.2. North America
- 10.2.1. Overview
- 10.2.2. Bispecific Antibodies Key Manufacturers in North America
- 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.2.7. U.S.
  - 10.2.7.1. Overview
  - 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.7.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.2.7.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.2.8. Canada
  - 10.2.8.1. Overview
  - 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.8.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.2.8.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3. Europe
- 10.3.1. Overview
- 10.3.2. Bispecific Antibodies Key Manufacturers in Europe
- 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.7. Germany
  - 10.3.7.1. Overview
  - 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.7.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.3.7.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.8. UK
  - 10.3.8.1. Overview
  - 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.8.3. UK Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.3.8.4. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.8.5. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.9. France
  - 10.3.9.1. Overview
  - 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.9.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.3.9.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.9.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.10. Italy
  - 10.3.10.1. Overview
  - 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.10.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.3.10.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.10.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.11. Spain
  - 10.3.11.1. Overview
  - 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.11.3. Spain Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.3.11.4. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.11.5. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.12. The Netherlands
  - 10.3.12.1. Overview
  - 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.12.3. The Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.3.12.4. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.12.5. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.13. Sweden
  - 10.3.13.1. Overview
  - 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.13.3. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.3.13.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.13.5. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.14. Russia
  - 10.3.14.1. Overview
  - 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.14.3. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.3.14.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.14.5. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.15. Poland
  - 10.3.15.1. Overview
  - 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.15.3. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.3.15.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.15.5. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.16. Rest of Europe
  - 10.3.16.1. Overview
  - 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.3.16.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.16.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
- 10.4.1. Overview
- 10.4.2. Bispecific Antibodies Key Manufacturers in Asia Pacific
- 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.4.4. APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.4.5. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.4.6. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.7. China
  - 10.4.7.1. Overview
  - 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.7.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.4.7.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.7.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.8. India
  - 10.4.8.1. Overview
  - 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.8.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.4.8.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.8.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.9. Japan
  - 10.4.9.1. Overview
  - 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.9.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.4.9.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.10. South Korea
  - 10.4.10.1. Overview
  - 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.10.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.4.10.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.11. Australia
  - 10.4.11.1. Overview
  - 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.11.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.4.11.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.12. Indonesia
  - 10.4.12.1. Overview
  - 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.12.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.4.12.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.12.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.13. Thailand
  - 10.4.13.1. Overview
  - 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.13.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.4.13.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.13.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.14. Philippines
  - 10.4.14.1. Overview
  - 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.14.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.4.14.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.15. Rest of APAC
  - 10.4.15.1. Overview
  - 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.4.15.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5. Latin America (LATAM)
- 10.5.1. Overview
- 10.5.2. Bispecific Antibodies Key Manufacturers in Latin America
- 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.5.4. LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.5.5. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.5.6. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.7. Brazil
  - 10.5.7.1. Overview
  - 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.7.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.5.7.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.8. Mexico
  - 10.5.8.1. Overview
  - 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.8.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.5.8.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.9. Argentina
  - 10.5.9.1. Overview
  - 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.9.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.5.9.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.10. Colombia
  - 10.5.10.1. Overview
  - 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.10.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.5.10.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.11. Rest of LATAM
  - 10.5.11.1. Overview
  - 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.5.11.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa (MEA)
- 10.6.1. Overview
- 10.6.2. Bispecific Antibodies Key Manufacturers in Middle East and Africa
- 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.6.4. MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 10.6.5. MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.6.6. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.7. Saudi Arabia
  - 10.6.7.1. Overview
  - 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.6.7.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.8. UAE
  - 10.6.8.1. Overview
  - 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.8.3. UAE Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.6.8.4. UAE Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.8.5. UAE Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.9. Israel
  - 10.6.9.1. Overview
  - 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.9.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.6.9.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.10. Turkey
  - 10.6.10.1. Overview
  - 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.10.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.6.10.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.11. Algeria
  - 10.6.11.1. Overview
  - 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.11.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.6.11.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.12. Egypt
  - 10.6.12.1. Overview
  - 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.12.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.6.12.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.13. Rest of MEA
  - 10.6.13.1. Overview
  - 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 10.6.13.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Bispecific Antibodies Industry

11.1. Competitive Dashboard
- 11.1.1. Competitive Benchmarking
- 11.1.2. Competitive Positioning
11.2. Company Profiles
- 11.2.1. Amgen
- 11.2.2. Genentech
- 11.2.3. Akeso, Inc.
- 11.2.4. Taisho Pharmaceutical
- 11.2.5. Janssen
- 11.2.6. Immunocore
- 11.2.7. Adimab, Innovent Biologics, Inc.
- 11.2.8. AstraZeneca
- 11.2.9. Affimed GmbH
- 11.2.10. Xencor
- 11.2.11. F. Hoffmann-La Roche Ltd.
- 11.2.12. Sanofi
- 11.2.13. Regeneron Pharmaceuticals Inc.
- 11.2.14. Pieris Pharmaceuticals, Inc.
- 11.2.15. Eli Lilly
- 11.2.16. Mereo BioPharma Group plc
- 11.2.17. Merus
- 11.2.18. MacroGenics, Inc.
- 11.2.19. Sobi, TG Therapeutics Inc.
- 11.2.20. Genmab A/S
- 11.2.21. Alteogen
- 11.2.22. Emergent BioSolutions Inc.
- 11.2.23. Novartis AG
- 11.2.24. Astellas Pharma Inc.
- 11.2.25. Celgene Corporation
- 11.2.26. Others